These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 5163816)

  • 1. Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
    Saletu B; Saletu M; Itil T; Marasa J
    Biol Psychiatry; 1971; 3(4):299-307. PubMed ID: 5163816
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
    Czobor P; Volavka J
    J Clin Psychopharmacol; 1993 Oct; 13(5):332-42. PubMed ID: 7693770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom patterns related to somatosensory evoked response differences within a schizophrenic population.
    Shagass C; Soskis DA; Straumanis JJ; Overton DA
    Biol Psychiatry; 1974 Aug; 9(1):25-43. PubMed ID: 4457116
    [No Abstract]   [Full Text] [Related]  

  • 5. A preliminary attempt to relate individual differences in EEG test dose response to clinical effect.
    May PR; Itil T; Van Putten T; Lee MA; Yale C
    Biol Psychiatry; 1982 May; 17(5):599-603. PubMed ID: 7093395
    [No Abstract]   [Full Text] [Related]  

  • 6. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 7. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to haloperidol dose reduction by Span of Apprehension measures for treatment-refractory schizophrenic patients.
    Green MF; Mintz J; Bowen L; Marshall BD; Kuehnel TG; Hayden JL; Liberman RP
    Am J Psychiatry; 1993 Sep; 150(9):1415-6. PubMed ID: 8352355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimozide treatment of chronic schizophrenics as compared with haloperidol and penfluridol maintenance treatment. A multidisciplinary approach.
    Baro F; Van Lommel R; Dom R; De Mesmaecker L
    Acta Psychiatr Belg; 1972 Mar; 72(2):199-214. PubMed ID: 5056015
    [No Abstract]   [Full Text] [Related]  

  • 11. Delayed peak latency of the mismatch negativity in schizophrenics and alcoholics.
    Kathmann N; Wagner M; Rendtorff N; Engel RR
    Biol Psychiatry; 1995 May; 37(10):754-7. PubMed ID: 7640331
    [No Abstract]   [Full Text] [Related]  

  • 12. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral prediction of response to haloperidol: a test dose strategy.
    Neborsky R; Janowsky D; Munson E; Hornbeck C; Depry D
    J Clin Psychiatry; 1982 Apr; 43(4):157-8. PubMed ID: 7068547
    [No Abstract]   [Full Text] [Related]  

  • 14. Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics.
    Pacquay M; Brasseur F
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):46-9. PubMed ID: 798190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aqueous pineal extract in chronic schizophrenia.
    Bigelow LB
    Biol Psychiatry; 1974 Feb; 8(1):5-15. PubMed ID: 4592789
    [No Abstract]   [Full Text] [Related]  

  • 16. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
    Elizur A; Segal Z; Yeret A; Ben-David M
    Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
    [No Abstract]   [Full Text] [Related]  

  • 19. Haloperidol--new addition to the drug treatment of schizophrenia.
    Stewart A; Lafave HG; Segovia G
    Behav Neuropsychiatry; 1969 Oct; 1(7):23-8. PubMed ID: 4907607
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in cognition, attention and language in acute schizophrenia.
    Blum RA; Livingston PB; Shader RI
    Dis Nerv Syst; 1969 Jan; 30(1):31-6. PubMed ID: 5775757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.